Superdosagem da vacina 17DD contra febre amarela, em uma região do sul do Brasil

Carneiro, Marcelo; Lara, Beanir da Silva; Schimidt, Betina; Gais, Lediana

doi:10.1590/s0037-86822011000200025

Cited by 11 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a randomized, double-blinded, clinical trial, in which different doses of the vaccine were used, only one minor AE (local pain) was reported, and it was significantly correlated with a higher dose (52). In two Brazilian studies (in 1999 and 2009) in which 17DD vaccines erroneously given in higher doses (25 times and 10 times the normal dose respectively) were injected in a total of 63 patients (14 and 49 respectively), mostly adults, of both sexes, did not report an increase in major AEs; only one suspected YEL-AVD case occurred (in a 6-year-old girl, who had spontaneous resolution) (53, 54).…”

Section: Discussionmentioning

confidence: 99%

Yellow fever vaccine and risk of developing serious adverse events: a systematic review

Porudominsky¹,

Gotuzzo²

2018

Rev Panam Salud Publica

View full text Add to dashboard Cite

Objective To evaluate contraindications and precautions for the yellow fever vaccine (YFV) in risk populations. Methods A literature review was conducted by searching PubMed for “yellow fever vaccine” and “adverse events” (AEs); 207 studies were found, and 43 of them met the inclusion criteria and were included in a systematic review. Results The results for first dose of YFV in elderly patients were conflicting—some showed AEs while some showed benefits. Therefore, precaution and case-by-case decisionmaking for YFV in this population are advised. The same precautions are warranted for YFV in infants 6-8 months, with the vaccine contraindicated in those < 6 months old and safe after 9 months of age. YFV seems safe in the first trimester of pregnancy, and probably throughout gestation, as it was not associated with increased malformations. During breastfeeding, YFV continues to be controversial. The vaccine seems safe in people being treated with immunomodulatory or immunosuppressive therapy, people with immunosuppressive diseases, and solid organ and hematopoietic stem cell transplant patients; in stem cell transplants, however, a booster dose should only be applied once immunity is recovered. HlV-infected patients with a CD4+ count > 200 cells/mm 3 do not have increased risk of AEs from YFV. Egg allergy vaccination protocols seem to provide a safe way to immunize these patients. Conclusions YFV safety has been confirmed based on data from many vaccination campaigns and multiple studies. AEs seem more frequent after a first-time dose, mainly in risk groups, but this review evaluated YFV in several of the same risk groups and the vaccine was found to be safe in most of them.

show abstract

Section: Discussionmentioning

confidence: 99%

Yellow fever vaccine and risk of developing serious adverse events: a systematic review

Porudominsky¹,

Gotuzzo²

2018

Rev Panam Salud Publica

View full text Add to dashboard Cite

show abstract

“…The current study has not enough power to define if lower yellow fever vaccine doses may be followed by a decrease in serious adverse events, such as vaccine-associated viscerotropic disease. On the other hand, information about the effect of large doses administered inadvertently is scant, based in few individuals and does not permit conclusions 29 , 30 …”

Section: Discussionmentioning

confidence: 99%

17DD yellow fever vaccine

Felzemburgh

Maia

Farias

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Objective: To verify if the Bio-Manguinhos 17DD yellow fever vaccine (17DD-YFV) used in lower doses is as immunogenic and safe as the current formulation.Results: Doses from 27,476 IU to 587 IU induced similar seroconversion rates and neutralizing antibodies geometric mean titers (GMTs). Immunity of those who seroconverted to YF was maintained for 10 mo. Reactogenicity was low for all groups.Methods: Young and healthy adult males (n = 900) were recruited and randomized into 6 groups, to receive de-escalating doses of 17DD-YFV, from 27,476 IU to 31 IU. Blood samples were collected before vaccination (for neutralization tests to yellow fever, serology for dengue and clinical chemistry), 3 to 7 d after vaccination (for viremia and clinical chemistry) and 30 d after vaccination (for new yellow fever serology and clinical chemistry). Adverse events diaries were filled out by volunteers during 10 d after vaccination. Volunteers were retested for yellow fever and dengue antibodies 10 mo later. Seropositivity for dengue was found in 87.6% of volunteers before vaccination, but this had no significant influence on conclusions.Conclusion: In young healthy adults Bio-Manguinhos/Fiocruz yellow fever vaccine can be used in much lower doses than usual.International Register ISRCTN 38082350.

show abstract

“…Only one reported symptoms, which included abdominal pain and arm pain and which resolved following supportive intravenous fluid treatment. Three other studies in Brazil documented administration of a 10 to 25-fold overdose of 17-DD yellow fever vaccine among 64 individuals; only one person was hospitalized (for possible acute vis-cerotropism and eventually recovered) [23–25].…”

Section: Discussionmentioning

confidence: 99%

Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007–2017

Moro

Araña

Marquez

et al. 2019

Vaccine

View full text Add to dashboard Cite

Background: The administration of an extra dose of a vaccine may occur due to a programmatic error (e.g., vaccination error) when there is need to provide one of the antigens of a combination vaccine not readily available as a single antigen, or when there is need to provide immunization in a person with uncertain vaccination histories (e.g., refugees). There is little data available on the safety of an extra dose of vaccine. Objective: To assess for the presence of adverse events (AEs) most commonly reported following the administration of excess doses of vaccine in the Vaccine Adverse Event Reporting System (VAERS). Methods: We searched VAERS for US reports where an excess dose of vaccine was administered to a person received from 1/1/2007 through 1/26/2018. We reviewed medical records for all serious reports and a random sample of non-serious reports. The most common AEs among reports of excess dose of vaccine administered were compared with the corresponding AEs for all vaccines reported to VAERS during the same period. Results: Out of 366,815 total VAERS reports received, 5067 (1.4%) reported an excess dose of vaccine was administered; 3898 (76.9%) did not describe an adverse health event (AHE). The most common vaccines reported were trivalent inactivated influenza (15.4%), varicella (13.9%), hepatitis A (11.4%), and measles, mumps, rubella, varicella (11.1%). Among reports where only AHEs were reported, the most common were pyrexia (12.8%), injection site erythema (9.7%), injection site pain (8.9%), and headache (6.6%). The percentage of AHEs among these reports was comparable to all reports submitted to VAERS during the same study period. Conclusion: More than three-fourths of reports of an excess dose of vaccine did not describe an AHE. Among reports where an AHE event was reported, we did not observe any unexpected conditions or clustering of AEs.

show abstract

Superdosagem da vacina 17DD contra febre amarela, em uma região do sul do Brasil

Cited by 11 publications

References 2 publications

Yellow fever vaccine and risk of developing serious adverse events: a systematic review

Yellow fever vaccine and risk of developing serious adverse events: a systematic review

17DD yellow fever vaccine

Is there any harm in administering extra-doses of vaccine to a person? Excess doses of vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2007–2017

Contact Info

Product

Resources

About